# Civista Bancshares, Inc.: financial statements, quarterly

CIVB · Nasdaq · CIK 944745 · [Financials](/sectors/financials.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/civb.md) · [Financials](/companies/civb/financials.md) · [Filings](/companies/civb/filings.md) · [Insiders](/companies/civb/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/civb/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [5.1](/filings/0000950170-24-124617.md) | [11.3 d](/filings/0001193125-26-096836.md) | [5.7](/filings/0000950170-25-065834.md) | [5.8](/filings/0000950170-25-104198.md) | [5.2](/filings/0001193125-25-267194.md) | [2.5 d](/filings/0001193125-26-096836.md) | [4.8](/filings/0001193125-26-214922.md) | [5.1](/filings/0001193125-26-338386.md) | [6.2](/filings/0001193125-25-267194.md) | [3.0 d](/filings/0001193125-26-096836.md) | [4.8](/filings/0001193125-26-214922.md) | [5.7](/filings/0001193125-26-338386.md) |
| Interest expense | $m | [14.3](/filings/0000950170-23-062106.md) | [22.0 d](/filings/0000950170-24-031472.md) | [21.8](/filings/0000950170-24-056931.md) | [22.8](/filings/0000950170-24-094734.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Income tax | $m | [1.9](/filings/0000950170-24-124617.md) | [1.6 d](/filings/0001193125-26-096836.md) | [0.8](/filings/0000950170-25-065834.md) | [1.0](/filings/0000950170-25-104198.md) | [1.6](/filings/0001193125-25-267194.md) | [1.5 d](/filings/0001193125-26-096836.md) | [1.8](/filings/0001193125-26-214922.md) | [1.9](/filings/0001193125-26-338386.md) | [2.9](/filings/0001193125-25-267194.md) | [2.5 d](/filings/0001193125-26-096836.md) | [3.0](/filings/0001193125-26-214922.md) | [2.9](/filings/0001193125-26-338386.md) |
| Net income | $m | [10.4](/filings/0000950170-24-124617.md) | [9.7 d](/filings/0001193125-26-096836.md) | [6.4](/filings/0000950170-25-065834.md) | [7.1](/filings/0000950170-25-104198.md) | [8.4](/filings/0001193125-25-267194.md) | [9.9 d](/filings/0001193125-26-096836.md) | [10.2](/filings/0001193125-26-214922.md) | [11.0](/filings/0001193125-26-338386.md) | [12.8](/filings/0001193125-25-267194.md) | [12.3 d](/filings/0001193125-26-096836.md) | [15.0](/filings/0001193125-26-214922.md) | [14.3](/filings/0001193125-26-338386.md) |
| Diluted EPS | $ per share | [0.66](/filings/0000950170-24-124617.md) | not reported | [0.41](/filings/0000950170-25-065834.md) | [0.45](/filings/0000950170-25-104198.md) | [0.53](/filings/0001193125-25-267194.md) | not reported | [0.66](/filings/0001193125-26-214922.md) | [0.71](/filings/0001193125-26-338386.md) | [0.68](/filings/0001193125-25-267194.md) | not reported | [0.72](/filings/0001193125-26-214922.md) | [0.69](/filings/0001193125-26-338386.md) |
| Basic EPS | $ per share | [0.66](/filings/0000950170-24-124617.md) | not reported | [0.41](/filings/0000950170-25-065834.md) | [0.45](/filings/0000950170-25-104198.md) | [0.53](/filings/0001193125-25-267194.md) | not reported | [0.66](/filings/0001193125-26-214922.md) | [0.71](/filings/0001193125-26-338386.md) | [0.68](/filings/0001193125-25-267194.md) | not reported | [0.72](/filings/0001193125-26-214922.md) | [0.69](/filings/0001193125-26-338386.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Interest expense: us-gaap:InterestExpense
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Total assets | $m | [3,733](/filings/0000950170-23-062106.md) | [3,861](/filings/0000950170-25-035961.md) | [3,880](/filings/0000950170-24-056931.md) | [4,012](/filings/0000950170-24-094734.md) | [4,061](/filings/0000950170-24-124617.md) | [4,098](/filings/0001193125-26-096836.md) | [4,147](/filings/0000950170-25-065834.md) | [4,186](/filings/0000950170-25-104198.md) | [4,113](/filings/0001193125-25-267194.md) | [4,336](/filings/0001193125-26-338386.md) | [4,298](/filings/0001193125-26-214922.md) | [4,294](/filings/0001193125-26-338386.md) |
| Total liabilities | $m | [3,400](/filings/0000950170-23-062106.md) | [3,489](/filings/0000950170-25-035961.md) | [3,511](/filings/0000950170-24-056931.md) | [3,638](/filings/0000950170-24-094734.md) | [3,667](/filings/0000950170-24-124617.md) | [3,710](/filings/0001193125-26-096836.md) | [3,749](/filings/0000950170-25-065834.md) | [3,782](/filings/0000950170-25-104198.md) | [3,614](/filings/0001193125-25-267194.md) | [3,793](/filings/0001193125-26-338386.md) | [3,746](/filings/0001193125-26-214922.md) | [3,728](/filings/0001193125-26-338386.md) |
| Short-term borrowings | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [333](/filings/0000950170-24-124617.md) | [372](/filings/0001193125-26-096836.md) | [370](/filings/0000950170-25-104198.md) | [374](/filings/0001193125-25-267194.md) | [394](/filings/0001193125-25-267194.md) | [389](/filings/0001193125-26-338386.md) | [397](/filings/0001193125-26-338386.md) | [404](/filings/0001193125-26-338386.md) | [499](/filings/0001193125-25-267194.md) | [543](/filings/0001193125-26-338386.md) | [552](/filings/0001193125-26-338386.md) | [567](/filings/0001193125-26-338386.md) |

- Total assets: us-gaap:Assets
- Total liabilities: us-gaap:Liabilities
- Short-term borrowings: not reported
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [21.5 d](/filings/0000950170-24-124617.md) | [2.1 d](/filings/0001193125-26-096836.md) | [0.8](/filings/0000950170-25-065834.md) | [12.2 d](/filings/0000950170-25-104198.md) | [12.9 d](/filings/0001193125-25-267194.md) | [22.4 d](/filings/0001193125-26-096836.md) | [3.6](/filings/0001193125-26-214922.md) | [11.1 d](/filings/0001193125-26-338386.md) | [19.0 d](/filings/0001193125-25-267194.md) | [9.6 d](/filings/0001193125-26-096836.md) | [12.2](/filings/0001193125-26-214922.md) | [17.1 d](/filings/0001193125-26-338386.md) |
| Capital expenditure | $m | [0.8 d](/filings/0000950170-23-062106.md) | [1.3 d](/filings/0001193125-26-096836.md) | [0.1](/filings/0000950170-25-065834.md) | not reported | not reported | not reported | [0.2](/filings/0000950170-25-065834.md) | not reported | not reported | not reported | not reported | not reported |
| Dividends paid | $m | [2.5 d](/filings/0000950170-24-124617.md) | [2.5 d](/filings/0001193125-26-096836.md) | [2.5](/filings/0000950170-25-065834.md) | [2.5 d](/filings/0000950170-25-104198.md) | [2.5 d](/filings/0001193125-25-267194.md) | [2.5 d](/filings/0001193125-26-096836.md) | [2.6](/filings/0001193125-26-214922.md) | [2.6 d](/filings/0001193125-26-338386.md) | [3.3 d](/filings/0001193125-25-267194.md) | [3.3 d](/filings/0001193125-26-096836.md) | [3.7](/filings/0001193125-26-214922.md) | [3.7 d](/filings/0001193125-26-338386.md) |
| Share repurchases | $m | [1.5 d](/filings/0000950170-24-124617.md) | [0.0 d](/filings/0001193125-26-096836.md) | [0.2](/filings/0000950170-25-065834.md) | [0.0 d](/filings/0000950170-25-104198.md) | [0.0 d](/filings/0001193125-25-267194.md) | [0.0 d](/filings/0001193125-26-096836.md) | [0.2](/filings/0001193125-26-214922.md) | [0.0 d](/filings/0001193125-26-338386.md) | [0.0 d](/filings/0001193125-25-267194.md) | [0.0 d](/filings/0001193125-26-096836.md) | [0.3](/filings/0001193125-26-214922.md) | [0.0 d](/filings/0001193125-26-338386.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Dividends paid: us-gaap:PaymentsOfDividendsCommonStock
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q1 FY2019 (2019-03-31) | Q2 FY2019 (2019-06-30) | Q3 FY2019 (2019-09-30) | Q1 FY2020 (2020-03-31) | Q2 FY2020 (2020-06-30) | Q3 FY2020 (2020-09-30) | Q1 FY2021 (2021-03-31) | Q2 FY2021 (2021-06-30) | Q3 FY2021 (2021-09-30) | Q1 FY2022 (2022-03-31) | Q2 FY2022 (2022-06-30) | Q3 FY2022 (2022-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [16.9](/filings/0001564590-20-024162.md) | [16.9](/filings/0001564590-20-038906.md) | [16.8](/filings/0001564590-20-052498.md) | [16.5](/filings/0001564590-20-024162.md) | [16.0](/filings/0001564590-21-042610.md) | [16.0](/filings/0001564590-21-055704.md) | [15.8](/filings/0001564590-22-019264.md) | [15.5](/filings/0001564590-22-028747.md) | [15.1](/filings/0001564590-22-037200.md) | [14.9](/filings/0001564590-22-019264.md) | [14.5](/filings/0001564590-22-028747.md) | [15.3](/filings/0001564590-22-037200.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 20,794,238 at 2026-07-31, from the cover of the [10-Q filed 2026-08-06](/filings/0001193125-26-338386.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:29 ET. No prices; not investment advice.